ChiCTR2000037651 版本V1.1 版本创建时间2020/10/26 03:22:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000037651 

最近更新日期:

Date of Last Refreshed on:

2020-10-26 03:21:49 

注册时间:

Date of Registration:

2020-08-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

“均衡营养素膳食”对多囊卵巢综合征患者月经恢复及生育能力提升的治疗作用

Public title:

Effect of Well Balanced Nutrient Diet on Menstrual Recovery and Fertility Improvement in PCOS Patients

注册题目简写:

均衡营养素膳食对PCOS的治疗作用

English Acronym:

Well Balanced Nutrient Diet

研究课题的正式科学名称:

“均衡营养素膳食”对多囊卵巢综合征患者月经恢复及生育能力提升的治疗作用

Scientific title:

Effect of Well Balanced Nutrient Diet on Menstrual Recovery and Fertility Improvement in PCOS Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

高珊 

研究负责人:

高珊 

Applicant:

Shan Gao 

Study leader:

Gao Shan 

申请注册联系人电话:

Applicant telephone:

+86 13910599635

研究负责人电话:

Study leader's
telephone:

+86 13910599635

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

gaoshanmw@163.com

研究负责人电子邮件:

Study leader's E-mail:

gaoshanmw@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市石景山区京原路5号

研究负责人通讯地址:

北京市石景山区京原路5号

Applicant address:

5 Jingyuan Road, Shijingshan District, Beijing

Study leader's address:

5 Jingyuan Road, Shijingshan District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

100043

申请人所在单位:

首都医科大学附属北京朝阳医院

Applicant's institution:

Beijing Chaoyang Hospital,Capital Medical University

研究负责人所在单位:

首都医科大学附属北京朝阳医院

Affiliation of the Leader:

Beijing Chaoyang Hospital,Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-科-271

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京朝阳医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Chaoyang Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-05-11 00:00:00

伦理委员会联系人:

吕亚丽

Contact Name of the ethic committee:

Yali Lv

伦理委员会联系地址:

北京市朝阳区工体东路16号

Contact Address of the ethic committee:

16 Gongti Rpad East, Chaoyang District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10-85231484

伦理委员会联系人邮箱:

Contact email of the ethic committee:

cyylunli2019@163.com

研究实施负责(组长)单位:

首都医科大学附属北京朝阳医院

Primary sponsor:

Beijing Chaoyang Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市朝阳区工体南路8号

Primary sponsor's address:

8 Gongti Road South, Chaoyang District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

妇幼健康研究会

具体地址:

海淀区大慧寺路12号院

Institution
hospital:

Association for Maternal and Child Health Studies

Address:

12 Dahuisi Road, Haidian District

经费或物资来源:

妇幼健康研究会

Source(s) of funding:

Association for Maternal and Child Health Studies

研究疾病:

多囊卵巢综合征  

Target disease:

Polycystic Ovary Syndrome

研究疾病代码:

Target disease code:

研究类型:

治疗研究

Study type:

Treatment study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究计划拟将“均衡营养素膳食”推广应用到140家妇幼保健机构或二级医院,对入选机构医务人员进行系统培训,提高基层诊疗水平,纳入5000例患者, 探索其普遍性、一般性规律,寻找适合地区人群的重要治疗切点,研发功能性食品;进一步优化技术指南及临床路径,最终形成电子化体系,联合技术单位开发完善电子化平台;为国家生育、健康政策的制定提供数据支持。  

Objectives of Study:

This study plans to extend the "balanced nutrient diet" to 140 maternal and child health care institutions or secondary hospitals, to systematically train medical personnel in selected institutions, to improve the level of diagnosis and treatment at the grass-roots level, to include 5000 patients, to explore its universality and general laws, to find important treatment points suitable for the local population, to develop functional foods, to further optimize technical guidelines and clinical pathways, to form an electronic system, to develop and improve electronic platforms in conjunction with technical units, and to provide data support for the formulation of national fertility and health policies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

患有多囊卵巢综合征且超重或者肥胖的患者
1. 多囊卵巢综合征
1)符合《多囊卵巢综合征中国诊疗指南(2018》诊断标准的患者;
2)此前未应用二甲双胍治疗PCOS的患者;
3)此前未应用二甲双胍治疗糖尿病等其他疾病的患者;
2.超重和肥胖的患者
1)根据BMI(Body Mass Index,简称BMI)评价患者的标准体重,BMI是用体重千克数除以身高米数的平方得出的数字,是国际上常用的衡量人体胖瘦程度以及是否健康的一个标准。
2)根据中国参考标准,BMI≥24被认为是超重,BMI≥28被认为是肥胖;

Inclusion criteria

Patients with polycystic ovary syndrome and overweight or obese
1. polycystic ovary syndrome
1) patients who meet the Chinese diagnostic criteria of PCOS (2018);
2) patients who had not previously treated PCOS with metformin;
3) patients who had not previously treated other diseases such as diabetes with metformin;
2. overweight and obese patients
The standard weight of a patient 1) evaluated on the basis of BMI (Body Mass Index), BMI is the number of kilograms divided by the square of the number of meters in height, which is a commonly used international measure of weight and health.
2) BMI≥24 is considered overweight and BMI≥28 is considered obese according to the Chinese reference standard;

排除标准:

1)有其他严重疾病的患者,包括冠心病(心绞痛、心肌梗死、冠状动脉血管再生过程或心电图异常Q波出现(ECG))、中风(缺血性或出血性,包括短暂性脑缺血发作)等;
2)有营养障碍性疾病或会影响营养干预效果的严重胃肠道疾病的患者;
3)任何其他医疗条件认为最长生存时间低于5年的患者;
4)有药物滥用或慢性酗酒或酒精依赖等成瘾性倾向的患者;
5)对改变饮食习惯或遵照医嘱配合改善生活习惯有很大执行上的困难的患者或不能坚持随访的患者;
6)对二甲双胍过敏或者既往应用二甲双胍出现严重副反应不能耐受的患者。

Exclusion criteria:

Patients with 1) other serious diseases include coronary heart disease (angina pectoris, myocardial infarction, coronary artery regeneration process or abnormal ECG Q (ECG)), stroke (ischemic or hemorrhagic, including transient ischemic attack), etc.;
2) patients with severe gastrointestinal diseases with nutritional disorders or which may affect the effects of nutritional interventions;
3) any other medical condition that the maximum duration of survival is less than 5 years;
4) patients with addictive sexual tendencies such as substance abuse or chronic alcohol or alcohol dependence;
5) patients who have significant implementation difficulties in changing their eating habits or following doctor's orders to improve their living habits or who are unable to follow up;
6) allergy to metformin or severe side effects of previous use of metformin are intolerable.

研究实施时间:

Study execute time:

From 2019-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2022-06-01 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

5000

Group:

Case series

Sample size:

干预措施:

均衡营养素膳食

干预措施代码:

Intervention:

Well Balanced Nutrient Diet

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京朝阳医院 

单位级别:

市属三甲 

Institution
hospital:

Beijing Chaoyang Hospital,Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

月经周期

指标类型:

主要指标

Outcome:

Menstrual Recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

自然妊娠

指标类型:

次要指标

Outcome:

Natural Pregnancy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖代谢状态

指标类型:

次要指标

Outcome:

Glucose Tolerance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素抵抗

指标类型:

次要指标

Outcome:

Insulin Resistance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

次要指标

Outcome:

Blood Lipid

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性激素

指标类型:

次要指标

Outcome:

Sexual Hormones

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood Pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重指数

指标类型:

次要指标

Outcome:

Body Mass Indix

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood Routine Examination

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清铁

指标类型:

次要指标

Outcome:

Blood Serum Iron

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

铁蛋白

指标类型:

次要指标

Outcome:

Ferritin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

基因

指标类型:

次要指标

Outcome:

Gene

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子代身长、体重及生长发育

指标类型:

次要指标

Outcome:

Growth and development of offspring

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

次要指标

Outcome:

Intestinal flora

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Nonrandom

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年4月

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

April,2023

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-29 12:33:22